Table 1A

Continued

Cases (n)Controls (n)GSTM1 null, crude ORa (95% CI)GSTT1 null, crude OR (95% CI)GSTP1 (any Val), crude OR (95% CI)CYP1A1 (any Val), crude OR (95% CI)
297b,c450c2.95 (2.16–4.04)d1.60 (1.06–2.41)d
1623151.51 (1.03–2.21)2.30 (1.48–3.56)
39c,e,f37c,e,f2.38 (0.93–6.06)d,g
40i577i1.01 (0.53–1.92)d0.59 (0.20–1.71)d
75f200f1.34 (0.78–2.29)d
1871390.78 (0.50–1.21)d1.07 (0.59–1.97)d1.30 (0.70–2.41)d
94921.29 (0.72–2.31)d0.64 (0.17–2.34)d
90b,h900.96 (0.53–1.73)d2.57 (1.12–5.90)
20204.00 (0.98–16.27)d,g0.71 (0.14–3.66)d
82c,f63c,f1.96 (0.99–3.86)d2.34 (1.19–4.58)d
41f123f1.03 (0.50–2.12)d1.26 (0.61–2.58)d
1711800.71 (0.46–1.08)0.77 (0.45–1.31)
250c172c1.09 (0.74–1.60)d1.38 (0.82–2.30)d
250c172c1.23 (0.86–1.82)d
1061465.42 (2.83–10.38)d,g
921471.65 (0.98–2.80)0.88 (0.52–1.48)1.29 (0.76–2.18)
831221.91 (1.04–3.52)d
53533.02 (1.36–6.71)d0.58 (0.26–1.26)
156h4721.29 (0.90–1.86)d
3123001.22 (0.88–1.67)d1.01 (0.68–1.50)d
3801931.04 (0.64–1.70)d
398h219h1.18 (0.82–1.68)d0.99 (0.66–1.49)d1.39 (0.98–1.96)d
160h,i149i0.99 (0.62–1.59)0.91 (0.47–1.74)1.26 (0.78–2.04)d0.42 (0.18–0.99)
1451640.94 (0.60–1.46)d0.73 (0.44–1.21)d0.88 (0.55–1.41)d
109h332.43 (1.10–5.38)d,g
182i202i0.96 (0.64–1.46)d,g1.47 (0.84–2.58)d1.25 (0.81–1.92)d1.33 (0.58–3.06)d
185b,h2070.97 (0.65–1.44)d0.95 (0.58–1.56)d1.15 (0.68–1.93)d
235i,j2850.80 (0.57–1.13)d
1311312.58 (1.17–5.66)d
1542460.91 (0.60–1.38)d
1643441.34 (0.92–1.95)d
2452510.92 (0.65–1.32)d1.13 (0.69–1.86)d
1421422.24 (1.40–3.61)1.88 (1.17–3.03)d
98601.92 (0.99–3.74)d2.48 (0.87–7.06)d5.21 (2.37–11.43)d
1001001.04 (0.59–1.83)d
204i203c,i0.92 (0.62–1.35)d0.67 (0.41–1.09)d1.01 (0.68–1.49)d
186i42i2.37 (1.20–4.67)1.47 (0.71–3.02)
2621 911
4224334617681764
5333382916991585
1.23 (1.06–1.42)1.17 (0.98–1.40)1.10 (0.92–1.31)1.32 (0.95–1.82)
0.000.010.130.00
0.990.970.520.89
  • a OR, odds ratio; CI, confidence interval; NS, not specified.

  • b Prevalent and incident cases.

  • c All ever tobacco smokers and/or chewers.

  • d Odds ratio calculated.

  • e All drinkers.

  • f All males.

  • g Study excluded.

  • h Includes nasopharyngeal, maxillary sinus, and/or salivary gland cancers.

  • i Number of cases and controls genotyped varied for each gene, thus overall numbers are presented.